ReviewActa pharmacologica Sinica2010
Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
Review in Acta pharmacologica Sinica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- LncRNAInternational journal of molecular sciences · 2023Article
- Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion.Cancer biology & therapy · 2022Article
- Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy.Frontiers in bioengineering and biotechnology · 2022Article
- Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.Cell death & disease · 2021Article
- Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter.Cell death & disease · 2020Article
- Novel mutations inAmerican journal of cancer research · 2020Article
- SUN2: A potential therapeutic target in cancer.Oncology letters · 2019Review
- Biological Potential and Mechanism of Prodigiosin fromInternational journal of molecular sciences · 2018Article
- Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.Cancer science · 2018Article
- Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.Acta pharmacologica Sinica · 2017Article
- Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.Oncotarget · 2017Article
- The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.Oncotarget · 2015Article
- A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.The Journal of biological chemistry · 2015Article
- Standard of care and promising new agents for triple negative metastatic breast cancer.Cancers · 2014Review
- Article
- DNA repair: from genome maintenance to biomarker and therapeutic target.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Review
- PARP inhibitors in cancer therapy: promise, progress, and puzzles.Cancer cell · 2011Article
- PARP and cancer--if it's broke, don't fix it.The New England journal of medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, especially to those with specific defects. With AZD2281 and BSI-201 entering phase III clinical trials, the final application of PARP inhibitors in clinic would come true soon. This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.